

"Initiation of drug use, injecting and treatment"

Age specific analyses of NDTMS for ACMD(PWG) Pathways Work Programme

Michael Donmall & Andrew Jones National Dug Evidence Centre, University of Manchester

Note:

Please note: this short report is intended for internal use by the Prevention Working Group of the Advisory Council on the Misuse of Drugs and is not for public consumption or reproduction.

Please do not quote without permission of the authors.

Initiation of drug use, injecting and treatment

The National Drug Treatment Monitoring System (NDTMS) provides the largest source of information in England about problem drug users who have presented to a treatment service. These 'top end' problem drug users may not be wholly representative of the wider group of non-problematic drug users or indeed of those problematic users who have not yet accessed treatment. Nevertheless, this dataset provides a rich source of information.

NDTMS collects information on all individuals receiving a triage assessment for Tier 3 or 4 drug treatment. The paper based NDTMS system used in England between 2001 and 2004 included information on the self-reported age of first use of each reported drug used, the age at which any drugs were first injected and the age at which treatment for drug use was first received. Available English data from this period (covering eight of the nine English Government Office Regions for 2001 to 2003) was examined to illustrate:

- the ages at which specific drugs are first taken,
- the ages at which those drugs that lead individuals to seek treatment were first taken.
- the lag between first use of these drugs and first receipt of treatment, and
- the lag between first use of drugs, injecting and receiving treatment.

The data set employed for this analysis contained 140,000 individual treatment seekers, brief details of whom are presented in Table 1 below.

Table 1: Basic characteristics of 140,000 sample

| Characteristic | % |
|------------------|----|
| Male | 73 |
| Female | 27 |
| | |
| Main drug: | |
| Heroin | 68 |
| Amphetamine | 4 |
| Cocaine | 4 |
| Crack | 5 |
| Cannabis | 9 |
| Others | 10 |
| | |
| Ethnic category: | |
| White | 88 |
| Other | 12 |

Age first used specific drugs

Table 2 illustrates the median starting ages of all drugs reported in the Regions for which the information was available (the North of England). The first use of these drugs follows a more or less expected pattern and illustrates potential key age groups in the onset of specific types of drug use, namely experimental, legal or low classification drugs (solvents, alcohol, cannabis) in the early teens, 'party' drugs (ecstasy,

MANCHESTER

National

Drug Evidence

MANCHESTER

AND National
Drug
Evidence
Centre

hallucinogens, amphetamine) in the mid teens, 'problematic' drugs (heroin, cocaine, benzos) in the late teens and early twenties and crack and additional opiates through the remaining early twenties. The medians presented imply that 50% of all problematic drugs users included in this analysis started use of these specific drugs before or by the listed age.

Table 2: Median age of first use of drugs

| Drug | Median age 1 st use |
|------------------|--------------------------------|
| Solvents | 13 |
| Alcohol | 14 |
| Cannabis | 14 |
| Ecstasy | 16 |
| Hallucinogens | 16 |
| Amphetamine | 17 |
| Heroin | 19 |
| Cocaine | 20 |
| Benzodiazepines | 20 |
| Crack | 22 |
| Methadone | 22 |
| Other opiates | 24 |
| Anti Depressants | 26 |

Age first use main drug

The remainder of this analysis concentrates on treatment seekers 'main drugs', namely the drug creating the primary problem or which caused them to seek treatment at the time of presentation to a service. Primary, problem drug use started at an average age of 19 years and the distribution of starting ages is presented in Figure 1 below.

Figure 1: Distribution of first use of main problem drug.






Table 3: Proportion of users of selected drugs starting use by the age of 20 yrs

| Cannabis | 94% |
|-------------|-----|
| Amphetamine | 75% |
| Heroin | 59% |
| Cocaine | 51% |
| Crack | 42% |

Demographic differences in age of first use of main drug

Note: mean ages were used to enable tests of significance.

Gender: no overall difference in age of first use of drugs, although the females in the sample demonstrated later use of cannabis and amphetamine but earlier use of cocaine and crack (all by a difference of roughly one year, p<0.005).

Ethnicity: within the broad categories of White, Black and Asian, the age of first use generally differed between by approx 1 year between White and Asian clients, and a further 1.5 yrs between Asian and Black clients. The differences were drug specific, although the numbers available for analysis diminish for individual main drugs such that caution is required in interpreting the results. However, significant differences are listed below (p<0.005):

Heroin as main drug:

- White before Asian clients (by 1 year), Asian before Black clients (by 1.5 yrs) Crack as main drug:
 - White before Black clients (by 0.75 yrs)

Cannabis as main drug:


White before Asian clients (by 0.75 yrs)

Regional variations: many differences appeared between onset ages within English Regions, the most significant being the later onset (by 1 year) of main drug use by individuals attending services within London, primarily due to later use of heroin and the earlier onset of cannabis use (by 1 year) within the North West, Yorkshire & Humberside and North East.

Age first injected

MANCHESTER National Drug Evidence Centre


Figure 2: Distribution of age first injected any drug



Those treatment seekers who had injected first did so at a median age of 20 years. No significant differences appeared between males and females although Black and Asian clients first injected on average two to three years later than did White clients.

Age first treated

Figure 3: Distribution of age first treated





Demographic differences were observable in the distribution of age of first treatment.

- Females were, on average, first treated when one year younger than males;
- Those in the Black ethnic category were first treated when three years older than their White or Asian counterparts;
- Those seeking treatment in London were first treated when at least two years older than in other areas of England.

These results were also found when restricting the analysis to primary heroin users to control for any cross correlation between demographic categories and main drug types.

Given the differences in onset of different drugs it is clearly essential to look not only at age of first treatment but also at the lag between first use of problem drugs and subsequent treatment received.

Lag between first main drug use and first treatment

Although the most common age of seeking treatment coincided with the age of first use of the main problem drug, the distribution of the lag between the two was stretched out over 20 years with an average lag of three years.




Figure 4: Distribution of lag between first main drug use and first treatment

The following results within the examination of lag between first stated main drug use and first treatment were significant:

Males waited one year more than females to access treatment;

- Black clients waited 1.5 years longer than did White clients
- White clients waited 0.5 years longer than Asian clients.

MANCHESTER
1824

National
Drug
Evidence
Centre

Again, these results were confirmed with primary heroin users alone, to control for any cross correlation between demographic categories and main drug types.

Confirmation of results

The variables: gender, ethnicity, main drug type and region of report were entered into a multiple regression model (converting all continuous dependents to an 'above or below median' categorical), to confirm that significant differences presented in this report existed independently of the effects of other variables.

Michael Donmall Andrew Jones National Drug Evidence Centre, University of Manchester

Note:

Please note: this short report is intended for internal use by the Prevention Working Group of the Advisory Council on the Misuse of Drugs and is not for public consumption or reproduction.

Please do not quote without permission of the authors.